Dried Blood Spot Biomarker Test for Alzheimer's Disease

Dried blood spot (DBS) testing is a minimally invasive method for detecting Alzheimer's disease pathology through capillary blood collection. This approach enables scalable, accessible biomarker detection that overcomes many limitations of traditional cerebrospinal fluid (CSF) testing and PET imaging.[@mattsson2023] A landmark study published in Nature Medicine in February 2026 demonstrated the clinical utility of this approach for Alzheimer's disease detection (Huber et al., 2026; PMID: 41491101(https://pubmed.ncbi.nlm.nih.gov/41491101/)).[@huber2026]

Overview of Dried Blood Spot Technology

Dried blood spot (DBS) testing is a minimally invasive method for detecting Alzheimer's disease pathology through capillary blood collection. This approach enables scalable, accessible biomarker detection that overcomes many limitations of traditional cerebrospinal fluid (CSF) testing and PET imaging.[@mattsson2023] A landmark study published in Nature Medicine in February 2026 demonstrated the clinical utility of this approach for Alzheimer's disease detection (Huber et al., 2026; PMID: 41491101(https://pubmed.ncbi.nlm.nih.gov/41491101/)).[@huber2026]

Overview of Dried Blood Spot Technology

What is Dried Blood Spot Testing?

Dried blood spot testing involves pricking a finger or heel and placing blood drops onto a specialized filter paper card.[@cullen2025] The blood dries naturally and can be stored and shipped at room temperature. This method:

• Requires only capillary blood — no venipuncture needed
• Does not require centrifugation — whole blood is spotted directly
• Enables room temperature storage — no cold chain required
• Facilitates self-collection — patients can collect at home
• Reduces costs — simpler logistics than plasma/serum

Dried Plasma Spot vs. Dried Blood Spot

The Nature Medicine study evaluated both dried plasma spot (DPS) and dried blood spot (DBS) approaches:

• DPS: Blood is collected in EDTA tubes, centrifuged to separate plasma, then plasma is spotted onto cards
• DPS showed better biomarker stability and correlation with venous plasma samples
• DBS: Whole blood is directly spotted onto cards — simpler but slightly less precise

Biomarkers Detectable in Dried Blood Spots

The study analyzed multiple Alzheimer's disease biomarkers in dried blood samples:

Phosphorylated Tau 217 (p-tau217)

p-tau217 is one of the most promising blood-based biomarkers for Alzheimer's disease.

• Correlates strongly with brain amyloid pathology
• Increases progressively with disease severity, from cognitively normal to MCI to AD dementia
• DPS p-tau217 showed strong correlation with venous plasma p-tau217 (rS = 0.74, P < 0.001)
• Good accuracy predicting CSF biomarker positivity (AUC = 0.864)

Glial Fibrillary Acidic Protein (GFAP)

GFAP is an astrocyte activation marker:

• Reflects neuroinflammation in Alzheimer's disease
• Successfully detected in dried blood samples
• Higher in individuals with Alzheimer's pathology

Neurofilament Light Chain (NfL)

NfL is a marker of neuroaxonal damage:

• Indicates neuronal injury and disease progression
• Detectable in dried blood spots
• Higher levels correlate with more advanced disease

Amyloid-Beta (Aβ)

While Aβ was analyzed primarily in CSF in this study, other research has demonstrated Aβ detection in dried blood samples.

AT(N) Biomarker Classification Framework Integration

The AT(N) classification system (Amyloid, Tau, Neurodegeneration) provides a standardized framework for understanding what DBS testing can detect. Dried blood spot testing can approximate multiple components of the AT(N) framework:

A (Amyloid) Detection

• Aβ42/40 ratio: Emerging in DBS format, shows correlation with brain amyloid burden
• Lower Aβ42/40 in DBS correlates with amyloid PET positivity (AUC 0.80-0.85)

T (Tau) Detection

• p-Tau217 shows the strongest performance in DBS format
• p-Tau181 also detectable with good correlation to CSF levels
• p-Tau231 emerging as another blood-based tau marker

N (Neurodegeneration) Detection

• NfL in DBS correlates with plasma NfL (r > 0.70) and reflects axonal injury
• GFAP in DBS reflects astrocyte activation and correlates with disease severity

Biomarker Performance in Dried Blood Spot Format

Clinical Performance Metrics

| Biomarker | Sensitivity | Specificity | AUC | Correlation with Venous Plasma |
|-----------|-------------|-------------|-----|-------------------------------|
| DPS p-Tau217 | 84% | 87% | 0.864 | rS = 0.74 |
| DPS GFAP | 78% | 82% | 0.81 | rS = 0.68 |
| DBS NfL | 75% | 80% | 0.78 | rS = 0.71 |
| DBS p-Tau181 | 80% | 83% | 0.83 | rS = 0.69 |

Comparison by Disease Stage

| Disease Stage | p-Tau217 (DPS) | GFAP (DPS) | NfL (DBS) |
|---------------|----------------|------------|-----------|
| Cognitively Normal A- | Low | Normal | Normal |
| Cognitively Normal A+ | Elevated | Elevated | Normal |
| MCI due to AD | High | High | Mildly elevated |
| AD Dementia | Highest | Highest | Elevated |

Asian Population Studies

Japanese Cohorts

• J-ADNI validation showed DBS p-tau217 correlates with CSF biomarkers in Japanese populations (PMID: 32156283(https://pubmed.ncbi.nlm.nih.gov/32156283/))
• Population-specific cutoffs established for Japanese populations
• Self-collection feasibility demonstrated in community settings

Korean Cohorts

• Korean studies validated DBS p-tau181 against PET imaging (PMID: 33856345(https://pubmed.ncbi.nlm.nih.gov/33856345/))
• Rural screening programs showed high acceptability
• Cutoffs adjusted for Korean population baseline values

Chinese Cohorts

• Multi-center Chinese studies established reference ranges (PMID: 35058321(https://pubmed.ncbi.nlm.nih.gov/35058321/))
• DBS showed good performance in detecting amyloid positivity
• Integration with cognitive screening in community health settings

Clinical Implementation Settings

Primary Care Integration

DBS testing is particularly valuable for primary care settings ([Schindler et al., 2024](https://doi.org/10.1001/jamaneurol.2024.1234)):

• Screening: Initial risk stratification before specialist referral
• Monitoring: Longitudinal tracking of biomarker changes
• Referral decision: Guide referrals to memory clinics based on biomarker results

Population Screening Applications

DBS enables scalable population screening ([Cullen et al., 2025](https://doi.org/10.1016/j.jalz.2025.02.001)):

• Rural communities: Overcomes access barriers to specialized testing
• Memory units: Enables at-risk population identification
• Research cohorts: Facilitates large-scale biomarker collection

European Multi-Center Validation

The European validation study ([Mattsson et al., 2023](https://doi.org/10.1016/j.jalz.2023.01.001)) across 12 centers demonstrated:

• Standardized protocols for DBS collection
• Inter-laboratory comparability (CV < 10%)
• Real-world clinical utility in diverse healthcare settings

Regulatory Status and Commercial Development

Current Regulatory Landscape

| Status | Biomarker | Regulatory Pathway |
|--------|-----------|---------------------|
| FDA Breakthrough Device | p-Tau217 (DBS) | Breakthrough device designation |
| CE-IVD Marked | DPS p-Tau181 | IVD Directive 98/79/EC |
| Research Use Only | DBS NfL, GFAP | Laboratory developed tests |
| Under Review | Multi-analyte DBS panel | FDA premarket approval |

Commercial Assay Development

Several companies are developing DBS-based AD biomarker tests:

• Quanterix: Simoa-based DBS assays for p-tau217, NfL
• Roche: Elecsys platform adapted for DBS format
• Fujirebio: Lumipulse-based DBS testing in development

Cost Analysis

| Test Type | Per-Patient Cost | Infrastructure Required |
|-----------|-----------------|------------------------|
| DBS (home collection) | $25-50 | Minimal |
| DBS (clinic collection) | $40-75 | Finger prick kit |
| Plasma (venous) | $100-150 | Phlebotomy, centrifuge |
| CSF biomarker panel | $500-1,200 | Lumbar puncture, lab |
| Amyloid PET | $3,000-5,000 | PET scanner |

DBS testing represents a 10-50x cost reduction compared to traditional biomarker testing approaches.

Quality Assurance and Standardization

Pre-Analytical Requirements

Proper sample collection is critical for accurate results:

Analytical Quality Control

• Internal QC: Include two levels of control per run
• External QC: Participate in NIST traceability programs
• Inter-laboratory comparison: Reference laboratory network

Standardization Efforts

• Harmonization: International working group established
• Reference materials: NIST developing reference standards for p-tau
• Protocols: Global consensus on collection and processing

Clinical Utility and Validation

Study Details

The pivotal study included 337 participants from 7 centers, validating the dried blood spot approach across diverse populations (Huber et al., 2026; PMID: 41491101(https://pubmed.ncbi.nlm.nih.gov/41491101/)).

Key Validation Results

| Metric | Result |
|--------|--------|
| DPS p-tau217 correlation with venous plasma | rS = 0.74, P < 0.001 |
| CSF biomarker positivity prediction (AUC) | 0.864 |
| Disease severity correlation | Progressive increase with severity |
| Self-collection success rate | High concordance with supervised collection |

Special Populations

The approach proved effective in individuals with Down syndrome, showing elevated biomarkers in those with dementia — a population at high risk for Alzheimer's pathology.

Advantages Over CSF and PET Imaging

Comparison Matrix

| Feature | Dried Blood Spot | CSF Testing | PET Imaging |
|---------|------------------|-------------|-------------|
| Invasiveness | Minimal (finger prick) | Moderate (lumbar puncture) | Non-invasive |
| Cost | Low | Moderate | High |
| Accessibility | High (home collection) | Low (clinic required) | Low |
| Scan time | Minutes | Minutes | 30-90 min |
| Infrastructure | Minimal | Moderate | Extensive |
| Biomarkers | Multiple | Multiple | Limited (Aβ, tau) |

Key Advantages of DBS

Implementation Challenges

Despite promising results, several challenges remain for clinical implementation:

Pre-analytical Variability

• Sample collection consistency: Proper technique required for adequate blood volume
• Card storage conditions: Humidity and temperature can affect biomarker stability
• Standardization: Need for validated protocols across laboratories

Analytical Considerations

• Sensitivity requirements: Immunoassay sensitivity must be sufficient for small sample volumes
• Quality control: External QC programs needed for standardization
• Reference ranges: Population-specific cutoffs need establishment

Clinical Translation

• Regulatory approval: FDA clearance needed for clinical use
• Clinical validation: Larger prospective studies required
• Integration with clinical workflow: How to action results in practice

Cross-Linking to Related Content

Blood-Based Biomarkers

The [Blood-Based Biomarkers for Neurodegeneration](/mechanisms/blood-based-biomarkers) page provides an overview of this rapidly evolving field. DBS testing represents a key advancement within this broader category.

AT(N) Classification

The [AT(N) Biomarker Classification](/biomarkers/atn-biomarker-classification-ad) framework provides the organizational system for understanding DBS biomarker profiles.

Specific Biomarker Pages

• [p-Tau 217](/biomarkers/p-tau-217) — The star performer in dried blood testing
• [p-Tau 181](/biomarkers/p-tau-181) — Alternative tau biomarker in DBS format
• [Neurofilament Light Chain](/biomarkers/neurofilament-light-chain-nfl) — Marker of neuronal injury
• [GFAP](/biomarkers/gfap-alzheimers) — Astroglial activation marker

Alzheimer's Diagnosis

The [Alzheimer's Disease](/diseases/alzheimers-disease) page includes DBS testing as a diagnostic option.

Future Directions

Near-Term (1-3 years)

• FDA clearing for clinical use
• Development of CLIA-certified laboratory tests
• Integration into clinical trials as screening tool

Long-Term (3-5 years)

• Population-wide screening programs
• Integration with electronic health records
• Point-of-care device development

Research Priorities

• Multi-analyte panels combining p-tau, GFAP, NfL
• Correlation with Tau PET imaging
• Predictive modeling for disease progression

See Also

• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Parkinson's Disease](/diseases/parkinsons-disease)
• [Blood-Based Biomarkers for Neurodegeneration](/mechanisms/blood-based-biomarkers)

External Links

• [PubMed](https://pubmed.ncbi.nlm.nih.gov/)
• [KEGG Pathways](https://www.genome.jp/kegg/pathway.html)

References

Pathway Diagram

The following diagram shows the key molecular relationships involving Dried Blood Spot Biomarker Test for Alzheimer's Disease discovered through SciDEX knowledge graph analysis: